Should the Cardiologist Bother About Fatty Liver?
Indian Journal of Clinical Cardiology · 2026-03 · 7 (1) · 7-8
DOI: 10.1177/26324636261425064 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Clinical Cardiology, online erschienen am 16.03.2026. Verfasst von A.N. Patnaik. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The nonalcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is defined as the presence of more than 5% of fat in hepatocytes and is nothing but a hepatic manifestation of a multi-system metabolic disorder, in the absence of causes like alcohol consumption, medications, diseases, or hereditary causes. For precise diagnosis, staging, and grading of MASLD, liver biopsy is the gold standard. However, non-invasive evaluation is done based on various tests and indices that include FIB-4, NAFLD fibrosis score, enhanced liver fibrosis (ELF), vibration-controlled transient elastography (VCTE/ FibroScan), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) proton density fat fraction. Metabolic dysfunction-associated steatohepatitis, previously called nonalcoholic steatohepatitis (NASH), is an advanced stage of MASLD. 1
Zitieren
APA
Patnaik, A. (2026). Should the Cardiologist Bother About Fatty Liver?. Indian Journal of Clinical Cardiology, 7(1), 7-8. https://doi.org/10.1177/26324636261425064
Vancouver
Patnaik A. Should the Cardiologist Bother About Fatty Liver?. Indian Journal of Clinical Cardiology. 2026;7(1):7-8. doi:10.1177/26324636261425064
BibTeX
@article{Patnaik2026,
author = {Patnaik, A.N.},
title = {Should the Cardiologist Bother About Fatty Liver?},
journal = {Indian Journal of Clinical Cardiology},
year = {2026},
volume = {7},
number = {1},
pages = {7--8},
doi = {10.1177/26324636261425064}
}
EUVIMED